AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Method to Obtain Hematopoietic Stem Cells

Detailed Technology Description: None

Supplementary Information: Patent Number: US20110311492A1
Application Number: US13132283A
Inventor: Verfaillie, Catherine | Buckley, Shannon Mychel | Khurana, Satish
Priority Date: 1 Dec 2008
Priority Number: US20110311492A1
Application Date: 21 Jul 2011
Publication Date: 22 Dec 2011
IPC Current: A61K003512 | A61K003802 | A61K003818 | A61P000700 | C12N00050789
US Class: 4240937 | 435375 | 5140076 | 5140135
Title: MAINTENANCE/EXPANSION OF HSC's
Usefulness: MAINTENANCE/EXPANSION OF HSC's
Summary: The methods are useful for maintaining/expanding HSCs; preparing a composition; and treating a non-malignant blood disorder, a metabolic storage disorder, or cancer. The cell, composition, HSCs which have been contacted with the factors, and the factors are useful in medical therapy for treating a non-malignant blood disorder, a metabolic storage disorder, or cancer. The non-malignant blood disorder is selected from immunodeficiencies comprising severe combined immunodeficiency (SCID), Fanconi's anemia, aplastic anemia, or congenital hemoglobinopathy. The metabolic storage disease is Hurler's disease, Hunter's disease, or mannosidosis. Cancer is selected from hematological malignancies comprising acute leukemia, chronic leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome, or non-hematological cancer. The chronic leukemia is myeloid or lymphoid. The lymphoma is Hodgkin's or non-Hodgkin's lymphoma. The non-hematological cancer is breast carcinoma, colon carcinoma, neuroblastoma, or renal cell carcinoma (all claimed).
Novelty: Maintaining/expanding hematopoietic stem cells (HSCs) by contacting HSCs with exogenous factors, e.g. tissue factor pathway inhibitor (TFPI) or defensin related cryptdin 3 (DEFCR3) or its biologically active fragment or derivative

Industry: Disease Diagnostic/Treatment

Sub Category: Cancer/Tumor

*Abstract: New method to obtain hematopoietic stem cells with increased engraftment potential to treat blood-based cancers.

*Principal Investigator: Name: Shannon Buckley
Department: University of Leuven

Name: Catherine Verfaillie, MDm, PhD, Professor
Department: University of Leuven

Country/Region: USA

For more information, please click Here